Cytokines as potential vaccine adjuvants.
There is a compelling clinical need for adjuvants suitable for human use to enhance the efficacy of vaccines in the prevention of life-threatening infection. Candidate populations for such vaccine-adjuvant strategies include normal individuals at the two extremes of life, as well as the ever increasing population of immunocompromised individuals. In addition, adjuvants that would increase the efficiency of vaccination with such vaccines as those directed against hepatitis B and Streptococcus pneumoniae would have an even greater general use. Cytokines, as natural peptides intimately involved in the normal immune response, have great appeal as potential adjuvants. An increasing body of work utilizing recombinant versions of interleukin-1, -2, -3, -6, -12, gamma-interferon, tumor necrosis factor, and granulocyte-monocyte-colony stimulating factor has shown that cytokines do have vaccine adjuvant activity. However, in order to optimize adjuvant effect and minimize systemic toxicity, strategies in which the cytokine is fused to the antigen, or the cytokine is presented within liposomes or microspheres appear to be necessary to make this a practical approach suitable for human use. There is much promise in this approach, but there is much work to be accomplished in order to optimize the pharmacokinetics of cytokine administration as well as its side effect profile.
Nohria
A
A
Center for Experimental Pharmacology and Therapeutics, Harvard-M.I.T. Division of Health Sciences and Technology, Cambridge, Massachusetts 02142.
Rubin
R H
RH
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001428:Bacterial Vaccines / Q000627:therapeutic use; D016207:Cytokines / Q000627:therapeutic use*; D004357:Drug Synergism; D006801:Humans; D007167:Immunotherapy; D051379:Mice; D014765:Viral Vaccines / Q000627:therapeutic use
D000276:Adjuvants, Immunologic; D001428:Bacterial Vaccines; D016207:Cytokines; D014765:Viral Vaccines